Table 5.
Changes in cardiac biomarkers and echocardiography at 1 month and final visit for participants randomised to spironolactone or control
| Biomarkers of cardiac function and echocardiographic variables | ||||||||
|---|---|---|---|---|---|---|---|---|
| One month |
End of trial |
|||||||
| Control | Spironolactone | P | Control | Spironolactone | P | |||
| N | 257 | 259 | 255 | 251 | ||||
| Mean change (SD) | Mean difference (95% CI) | Mean (SD) change | Mean difference (95% CI) | |||||
| NT-proBNP ng/L | +9 | −47 (143) | −57 (−81; −33) | <0.001 | +26 (212) | −20 (167) | −43 (−75 to −11) | 0.009 |
| hsTnT ng/L | 0.0 | 0.0 | 0.0 | 0.809 | 0.0 | 0.1 | 0.0 (0.0 to +0.1 | 0.113 |
| GDF-15 ng/L | 0.0 | 0.9 | 0.0 | 0.939 | 0.1 | 0.1 | 0.0 (0.0 to +0.1) | 0.095 |
| Mean (SD) change | Mean (SD) change | |||||||
| QRS (ms) | 0 (10) | 0 (14) | 0 (−2 to +2) | 0.345 | +1 (10) | −2 (10) | −3 (−5 to −1) | 0.003 |
| LVEDVi (mL/m2) | −2 (5) | −1 (5) | 0 (−1 to +2) | 0.551 | −1 (4) | −1 (4) | 0 (−1 to +1) | 0.984 |
| LVEF (%) | +0.7 (4.8) | +0.3 (5.3) | −0.5 (−1.7 to +0.7) | 0.404 | −0.4 (4.4) | +0.8 (4.2) | +1.2 (+0.2 to +2.2) | 0.022 |
| LVMi (g/m2) | 0 (12) | −1 (14) | −1 (−4 to +1) | 0.296 | −1 (12) | −3 (13) | −2 (−4 to 0) | 0.079 |
| LAVI (mL/m2) | 0 (5) | −1 (4) | −1 (−2 to 0) | 0.072 | 0 (5) | −2 (5) | −1 (−2 to 0) | 0.010 |
| E m/s | +0.02 (0.13) | −0.04 (0.14) | −0.06 (−0.08 to −0.03) | <0.001 | +0.01 (0.14) | −0.04 (0.14) | −0.05 (−0.07 to −0.02) | <0.001 |
| A m/s | −0.01 (0.12) | −0.02 (0.12) | 0.00 (−0.03 to 0.02) | 0.855 | 0.00 (0.013) | −0.02 (0.14) | −0.01 (−0.04 to +0.01) | 0.268 |
| E/A | +0.05 (0.22) | −0.04 (0.23) | −0.10 (−0.14 to −0.05) | <0.001 | +0.03 (0.30) | −0.04 (0.28) | −0.07 (−0.12 to −0.01) | 0.015 |
| E/e’ | +0.05 (2.43) | −0.22 (2.3) | −0.22 (−0.68 to +0.25) | 0.363 | −0.02 (2.66) | −0.34 (2.30) | −0.38 (−0.83 to 0.08) | 0.103 |
| TAPSE | −0.6 (5.2) | −0.3 (5.2) | −0.1 (−1.0 to +0.9) | 0.887 | 0.0 (5.3) | −0.3 (5.3) | −0.5 (−1.4 to +0.5) | 0.305 |
A, late (atrial) mitral flow velocity; E, early mitral flow velocity; eʹ, early diastolic tissue velocity; GDF-15, growth differentiation factor-15; hsTnT, high-sensitivity troponin-T; LAVI, left atrial volume index; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion.
Values shown in bold are significant at a P-value <0.05